352 Results
Sort By:
Published on March 6, 2024
A U.K. study has shown that prostate cancer can be classified into two distinct prostate cancer subtypes according to how gene mutations evolve within the tumors, with one type linked to more aggressive disease than the other. The discovery was made by an international team, led by the University of…
Published on January 24, 2024
New research has revealed that the receptor protein known as CHRM1 was identified as a key driver for docetaxel-resistant prostate cancer. Led by a team of scientists at Washington State University, the study showed that inhibiting CHRM1 restored docetaxel’s ability to kill cells and stop tumor growth. The researchers suggest…
Published on January 17, 2024
Researchers from Dana-Farber Cancer Institute and the University of Trento, Italy, report in Cancer Discovery, that they have developed a new blood test differentiates neuroendocrine prostate cancer (NEPC) once it has advanced from adenocarcinoma. Having a non-invasive method to detect this switch has important implications for this hard-to-treat form of…
Published on December 4, 2023
Two separate studies led by researchers from the UCLA Jonsson Comprehensive Cancer Center show why some prostate cancers can become resistant to hormone therapies—the most common treatment for men with advanced stage disease. The new research efforts provide new information about how cells use the energy to influence the way…
Published on November 6, 2023
While it is well documented that Black men in the United States are more likely to develop prostate cancer than White men and have more advanced disease at diagnosis than their White counterparts, limited data is available to help guide prostate-specific antigen (PSA) testing for this at-risk population. Now, new…
Published on October 19, 2023
Cedars-Sinai Cancer investigators have identified two promising new treatment options for men with non-metastatic recurrent prostate cancer—enzalutamide (Astellas and Pfizer’s Xtandi) with androgen deprivation therapy (ADT), or enzalutamide alone. Each of these regimens beat the current standard treatment, which is ADT alone. The combination of ADT plus enzalutamide reduced the…
Published on October 2, 2023
New data presented Sunday at the American Society for Radiation Oncology (ASTRO) Annual Meeting shows that precision medicine navigators (PMNs) increased the rate of genetic testing in Black prostate cancer patients six-fold. The findings have the potential to significantly reduce the health inequities and improve health outcomes for black patients.…
Published on September 27, 2023
One of the largest research efforts studying genes associated with prostate cancer reveals that mutations in 11 genes are associated with aggressive disease. The study, which analyzed samples from 17,500 cancer patients and published in JAMA Oncology, found mutations in several genes not already included in common prostate cancer genetic…
Published on August 23, 2023
In a first-of-its-kind study, researchers at University College London (UCL) have conducted a clinical trial to use MRI scans with PSA (prostate specific antigen) to aid in prostate cancer screening and assess the need for additional testing. The research, published in BMJ Oncology, showed that of the 29 participants in…
Published on August 16, 2023
City of Hope researchers have identified four metabolism-related biomarkers that may be associated with an increased risk for metastatic prostate cancer in men of West African heritage and could one day be incorporated into a disease prediction tool for this high-risk population. “We hope that our findings can become part…
Published on August 16, 2023
A $2.5 million five-year grant from the National Cancer Institute (NCI) will aid a University of Miami researcher to lead an effort to develop a urine test to detect prostate cancer. The research grant will be led by Sanoj Punnen, MD, co-chair of the Genitourinary Site Disease Group at the…
Published on August 15, 2023
Medical genetics company Invitae announced that data from its PROCLAIM clinical trial shows the benefit of pathogenic germline variant (PGV) testing for all prostate cancer patients. According to the data, nearly half of all prostate cancer patients with clinically actionable inherited PGVs could be missing out on vital, targeted care…
Published on August 9, 2023
Investigators at UT Southwestern Medical Center have published research this week in the journal Cancer Cell that shows the loss of a gene in prostate tumors drives resistance to targeted therapies. The gene, known as SYNCRIP, unleashes cellular machinery that creates random mutations throughout the genome that drives the therapy…
Published on July 26, 2023
Magnetic resonance-guided daily adaptive stereotactic body radiotherapy (MRg-A-SBRT) significantly lowers the risk for acute genitourinary and gastrointestinal toxicity in patients with prostate cancer relative to standard computed tomography-guided non-adaptive prostate SBRT (CT-SBRT), shows a pooled analysis of previously published data. First author of the review, Jonathan Leeman, from the Dana‐Farber…
Published on July 13, 2023
Scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, have developed a first-of-its-kind, orally administered drug that can disrupt prostate cancer cell metabolism while simultaneously delivering the chemotherapy drug cisplatin directly into treatment-resistant prostate cancer cells. Cisplatin, a well established chemotherapy drug on the…